Predicts probability of acute urinary retention or surgical intervention within 2 years.
Predicts 5-year progression-free probability.
Predicts 6-month, 12-month and median survival.
Predicts 6-, 12- and 24-month survival probability.
Predicts 15-year risk of breast cancer specific death.
Predicts risk of additional node metastasis following complete axillary lymph node dissection.
Predicts 5-year risk of arm lymphedema.
Predicts risk of recurrence and mortality.
Predicts 96-month disease-specific survival.
Predicts the 5- and 10-year recurrence-free survival percentage.
Predicts 10-year colorectal cancer risk.
Predicts the probability of a positive test result.
Predicts the probability of hospitalization.
Predicts the probability of ICU admission or death from COVID-19.
Predicts 2-year based on clinical criteria alone or based on clinical criteria and EEG characteristics.
Predicts the probabilities of postoperative naming, verbal memory, and mood decline
Predicts the 1-year risk of recurrent seizure after temporal lobe epilepsy (TLE) surgery.
Predicts risk of any adverse event, bothersome stress, urge incontinence or positive stress test with 12 months of surgery.
Predicts risk of urinary incontinence to help identify patients who may benefit from more aggressive management.
Predicts postpartum urinary and fecal incontinence.
Predicts 30-day transfusion probability.
Predicts recurrent pelvic organ prolapse, surgical complications, and change in health status 12 months.
Predicts 12 and 20 year risk of pelvic floor disorders.
Predicts 30-day probability of infection after Cesarean Delivery.
Predicts 5- and 9-year disease-specific survival.
Predicts 1-, 3-, and 5-year overall survival and disease-specific mortality.
Predicts 30-day and 1-year risks of mortality, myocardial infarction, or revascularization.
Predicts 3-year probability of monomorphic ventricular tachycardia and polymorphic ventricular tachycardia / ventricular fibrillation.
Predicts the probability of cerebrovascular accidents using patient demographics and clinical characteristics.
Predicts 30-day all-cause mortality.
Predicts 3-, 5- and 10-year survival after exercise treadmill testing.
Predicts discharge to a long-term acute care hospital.
Predicts changes in semen parameters.
Predicts moderate to severe acute kidney injury.
Predicts the 5-year graft survival and 1-year eGFR value.
Prediction of certain outcomes after deceased-donor kidney transplantations.
Predicts 5- and 7-year freedom from recurrence and 7-year renal insufficiency.
Predicts 12-month progression-free survival with sunitinib or pazopanib.
Predicts the probability of malignant pathology for small renal masses.
Predicts Kidney Cancer Upstaging Risk.
Predicts the need of a patient to attend an extended care facility (ECF).
Predicts NAFLD histological score.
Predicts the probability of positive sentinel nodes.
Predicts probability of small choroidal melanoma.
Predicts the probability of passing the American Board of Internal Medicine examination.
Predicts 30-day probability of venous thromboembolisms(VTEs) post discharge.
Estimates the probability of presence of a serious adverse events.
Individualized Metabolic Surgery Score for Bariatric Procedure Selection.
Predicts the 10-year risk of major adverse cardiovascular events with and without undergoing weight loss surgery.
Predicts late relapse of diabetes following early postoperative diabetes remission
Predicts late relapse of type 2 diabetes.
Predicts 5-year percentage of recurrence-free survival to assist in determining the need for adjuvant treatment.
Predicts 5-year probability of survival.
Predicts 5 and 10-year risk of death, pancreas graft loss, and kidney graft loss.
Predicts 12-, 24- and 36-month survival.
Predict 5-year cancer specific survival and lymph node involvement.
Predicts percentage chance of having prostate cancer and of having high grade prostate cancer to help determine treatment options.
Determines 4-year probability of outcomes with or without dutasteride.
Predicts percentage of having prostate cancer with repeated prostate biopsy.
For patients who are undergoing prostate cancer screening with PSA and DRE.
For patients who are undergoing prostate cancer screening with PSA and DRE.
For patients who are undergoing prostate cancer screening with PSA and DRE.
Predicts the probability of upgrading the Gleason score in patients with low- and intermediate-grade prostate cancer on biopsy to help identify patients who may benefit from more aggressive or novel therapy.
Predicts 5- and 10-year probabilities for radical prostatectomy, watchful waiting, and 3-dimensional conformal radiation therapy of survival, indolent cancer, freedom from recurrence, metastasis and trifecta.
Predicts 7-, 9- and 10-year post-treatment freedom from recurrence, and 10- and 15-year cancer-specific mortality.
Predicts 7- and 9-year post-treatment freedom from recurrence.
Predicts the probability of freedom from biochemical failure at 5- and 10-year and cumulative incidence of metastasis at 5- and 10-year for men receiving salvage radiation therapy.
Predicts 5-, 10- and 15-year prostate cancer-specific mortality.
Predicts 1- and 2-year overall survival.
Predicts the conversion to psychosis for youth who are at high risk due to symptoms, genetic risk, and recent decline in functioning based on a variety of tests and psychometric dimensions.
Predicts postoperative rates of 12-year sarcoma-specific mortality.
Predicts 1-, 2- and 3-year risk of sarcoma-specific death following local recurrence.
Predicts 30-day infection risk of organ space surgical site infection.
Predicts probability of emergency department visit within 30 days, readmission within 30 days and reoperation for infection within 90 days. Predicts change in EQ-5D, PHQ-9 and PDQ quality-of-life metrics.
Predicts probability of thyroid cancer in thyroid nodules.
Predicts length of stay and chance of NOT returning home.
Predicts 6-year mortality.
Predicts 5-year risk of morbidity and mortality.
Predicts 5-Year Outcomes for Second-Line Therapies.
Predicts 7-year pouch retention probability.